It was reported that liensinine and neferine could inhibit the activities of acetylcholinesterase and cross the blood-brain barriers, suggesting their therapeutic potential for the management of Alzheimer’s disease. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.